ATARA Biotherapeutics (ATRA) Prices 12.63M Share Common Offering at $11.32/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
After-Hours Stock Movers 05/26: (CPIX) (HTZ) (STNE) Higher; (VSAT) (KEYS) (IIPR) Lower (more...)
May 26, 2020 5:49 PM EDTToday's After-Hours Stock Movers:
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) 37% HIGHER; announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis. Vibativ® (telavancin) is a potent, FDA-approved anti-infective for the treatment of serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia. It is also approved for complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.
Hertz Global Holdings,... More
ATARA Biotherapeutics (ATRA) Announces Proposed Common Share & Pre-Funded Warrants Offering
May 26, 2020 4:06 PM EDTAtara Biotherapeutics, Inc. (NASDAQ: ATRA) today announced that it has commenced an underwritten public offering of shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of its common stock. The pre-funded warrants will be offered at the same price per share as the common... More
ATARA Biotherapeutics (ATRA) Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive MS in Late-Breaking e-Poster at EAN
May 26, 2020 7:05 AM EDTAtara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of additional safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive... More
